Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration
Featured Stories
With new leadership, Creyon enters a $1B-plus deal with Lilly
Eli Lilly Partners with Creyon Bio for Accelerated Discovery and Development of RNA-Targeted Oligonucleotides for Various Diseases
Creyon and Eli Lilly Sign Licensing Deal Worth $1 Billion
With a New CEO, Oligonucleotide Biotech Creyon forges Eli Lilly partnership
Eli Lilly Pens Creyon AI Oligonucleotide Pact with $1B in Biobucks on the Table
Creyon Today Announced a Collaboration to Help Lilly Use its AI-Powered Oligo Engineering Platform and Aptamer-Based Delivery Approach to Discover and Develop Therapies in a Range of Diseases
Chutes & Ladders—Creyon Is Promoting Acting CEO Serge Messerlian to the Top Spot Permanently
Creyon Appoints Serge Messerlian as CEO to Advance AI-Driven Oligonucleotide Drug Development
Creyon Bio Names Industry Veteran Serge Messerlian as CEO, Sharpening Focus on RNA-Targeted Therapeutics